Effects of Low Dose Metformin on Metabolic Traits in Clozapine-Treated Schizophrenia Patients: An Exploratory Twelve-Week Randomized, Double-Blind, Placebo-Controlled Study.
Metformin has been used for alleviating metabolic abnormalities in patients with schizophrenia. The lowest dose of metformin to treat metabolic abnormalities in clozapine-treated patients is 1000 mg/d. This study was designed to determine whether metformin at 500 mg/d and 1000 mg/d is effective in i...
Main Authors: | , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2016-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC5156367?pdf=render |
id |
doaj-c79e3386155a4172ab44c156a92837e0 |
---|---|
record_format |
Article |
spelling |
doaj-c79e3386155a4172ab44c156a92837e02020-11-24T21:52:13ZengPublic Library of Science (PLoS)PLoS ONE1932-62032016-01-011112e016834710.1371/journal.pone.0168347Effects of Low Dose Metformin on Metabolic Traits in Clozapine-Treated Schizophrenia Patients: An Exploratory Twelve-Week Randomized, Double-Blind, Placebo-Controlled Study.Chih-Chiang ChiuMong-Liang LuMing-Chyi HuangPo-Yu ChenYen-Kuang LinShih-Ku LinChun-Hsin ChenMetformin has been used for alleviating metabolic abnormalities in patients with schizophrenia. The lowest dose of metformin to treat metabolic abnormalities in clozapine-treated patients is 1000 mg/d. This study was designed to determine whether metformin at 500 mg/d and 1000 mg/d is effective in improving the metabolic profiles of clozapine-treated patients with pre-existing metabolic abnormalities, and whether its effectiveness depends on metformin dosage.In this 12-week, randomized, double-blind, placebo-controlled trial, metformin at 500 mg/d or 1000 mg/d was prescribed to clozapine-treated patients with schizophrenia who had pre-existing metabolic abnormalities. The recruited patients underwent physical and laboratory evaluations at weeks 4, 8, and 12. The outcomes were any changes in metabolic traits.Among the 96 clozapine-treated patients with schizophrenia screened for the trial, 55 patients with pre-existing metabolic abnormalities were randomly assigned to placebo (n = 18), metformin dosage at 500 mg/d (n = 18), and metformin dosage at 1000 mg/d (n = 19) groups. The body weight (BW) of patients in the metformin 1000 mg/d group significantly decreased, by a mean of 0.97 kg over the 12 week trial period. Moreover, patients in the metformin at 500 mg/d and 1000 mg/d groups had a significant decrease in body mass index (BMI) after 12 weeks, with the mean decrease being 0.70 and 0.50 kg/m2, respectively. No significant changes were observed in the other metabolic parameters of patients in the three groups.Our results demonstrated that a low metformin dosage of either 500 mg/d or 1000 mg/d for 12 weeks slightly reduced the BW and BMI of clozapine-treated patients with pre-existing metabolic abnormalities. A longer period of treatment with a larger sample is warranted to determine the factors that influence the metformin treatment response.ClinicalTrials.gov NCT02751307.http://europepmc.org/articles/PMC5156367?pdf=render |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Chih-Chiang Chiu Mong-Liang Lu Ming-Chyi Huang Po-Yu Chen Yen-Kuang Lin Shih-Ku Lin Chun-Hsin Chen |
spellingShingle |
Chih-Chiang Chiu Mong-Liang Lu Ming-Chyi Huang Po-Yu Chen Yen-Kuang Lin Shih-Ku Lin Chun-Hsin Chen Effects of Low Dose Metformin on Metabolic Traits in Clozapine-Treated Schizophrenia Patients: An Exploratory Twelve-Week Randomized, Double-Blind, Placebo-Controlled Study. PLoS ONE |
author_facet |
Chih-Chiang Chiu Mong-Liang Lu Ming-Chyi Huang Po-Yu Chen Yen-Kuang Lin Shih-Ku Lin Chun-Hsin Chen |
author_sort |
Chih-Chiang Chiu |
title |
Effects of Low Dose Metformin on Metabolic Traits in Clozapine-Treated Schizophrenia Patients: An Exploratory Twelve-Week Randomized, Double-Blind, Placebo-Controlled Study. |
title_short |
Effects of Low Dose Metformin on Metabolic Traits in Clozapine-Treated Schizophrenia Patients: An Exploratory Twelve-Week Randomized, Double-Blind, Placebo-Controlled Study. |
title_full |
Effects of Low Dose Metformin on Metabolic Traits in Clozapine-Treated Schizophrenia Patients: An Exploratory Twelve-Week Randomized, Double-Blind, Placebo-Controlled Study. |
title_fullStr |
Effects of Low Dose Metformin on Metabolic Traits in Clozapine-Treated Schizophrenia Patients: An Exploratory Twelve-Week Randomized, Double-Blind, Placebo-Controlled Study. |
title_full_unstemmed |
Effects of Low Dose Metformin on Metabolic Traits in Clozapine-Treated Schizophrenia Patients: An Exploratory Twelve-Week Randomized, Double-Blind, Placebo-Controlled Study. |
title_sort |
effects of low dose metformin on metabolic traits in clozapine-treated schizophrenia patients: an exploratory twelve-week randomized, double-blind, placebo-controlled study. |
publisher |
Public Library of Science (PLoS) |
series |
PLoS ONE |
issn |
1932-6203 |
publishDate |
2016-01-01 |
description |
Metformin has been used for alleviating metabolic abnormalities in patients with schizophrenia. The lowest dose of metformin to treat metabolic abnormalities in clozapine-treated patients is 1000 mg/d. This study was designed to determine whether metformin at 500 mg/d and 1000 mg/d is effective in improving the metabolic profiles of clozapine-treated patients with pre-existing metabolic abnormalities, and whether its effectiveness depends on metformin dosage.In this 12-week, randomized, double-blind, placebo-controlled trial, metformin at 500 mg/d or 1000 mg/d was prescribed to clozapine-treated patients with schizophrenia who had pre-existing metabolic abnormalities. The recruited patients underwent physical and laboratory evaluations at weeks 4, 8, and 12. The outcomes were any changes in metabolic traits.Among the 96 clozapine-treated patients with schizophrenia screened for the trial, 55 patients with pre-existing metabolic abnormalities were randomly assigned to placebo (n = 18), metformin dosage at 500 mg/d (n = 18), and metformin dosage at 1000 mg/d (n = 19) groups. The body weight (BW) of patients in the metformin 1000 mg/d group significantly decreased, by a mean of 0.97 kg over the 12 week trial period. Moreover, patients in the metformin at 500 mg/d and 1000 mg/d groups had a significant decrease in body mass index (BMI) after 12 weeks, with the mean decrease being 0.70 and 0.50 kg/m2, respectively. No significant changes were observed in the other metabolic parameters of patients in the three groups.Our results demonstrated that a low metformin dosage of either 500 mg/d or 1000 mg/d for 12 weeks slightly reduced the BW and BMI of clozapine-treated patients with pre-existing metabolic abnormalities. A longer period of treatment with a larger sample is warranted to determine the factors that influence the metformin treatment response.ClinicalTrials.gov NCT02751307. |
url |
http://europepmc.org/articles/PMC5156367?pdf=render |
work_keys_str_mv |
AT chihchiangchiu effectsoflowdosemetforminonmetabolictraitsinclozapinetreatedschizophreniapatientsanexploratorytwelveweekrandomizeddoubleblindplacebocontrolledstudy AT monglianglu effectsoflowdosemetforminonmetabolictraitsinclozapinetreatedschizophreniapatientsanexploratorytwelveweekrandomizeddoubleblindplacebocontrolledstudy AT mingchyihuang effectsoflowdosemetforminonmetabolictraitsinclozapinetreatedschizophreniapatientsanexploratorytwelveweekrandomizeddoubleblindplacebocontrolledstudy AT poyuchen effectsoflowdosemetforminonmetabolictraitsinclozapinetreatedschizophreniapatientsanexploratorytwelveweekrandomizeddoubleblindplacebocontrolledstudy AT yenkuanglin effectsoflowdosemetforminonmetabolictraitsinclozapinetreatedschizophreniapatientsanexploratorytwelveweekrandomizeddoubleblindplacebocontrolledstudy AT shihkulin effectsoflowdosemetforminonmetabolictraitsinclozapinetreatedschizophreniapatientsanexploratorytwelveweekrandomizeddoubleblindplacebocontrolledstudy AT chunhsinchen effectsoflowdosemetforminonmetabolictraitsinclozapinetreatedschizophreniapatientsanexploratorytwelveweekrandomizeddoubleblindplacebocontrolledstudy |
_version_ |
1725876078207041536 |